Ramosetron, low dose midazolam, and their combination for the prevention of postoperative nausea and vomiting in patients undergoing thyroidectomy

Phase 4

• Conditions: postoperative nausea and vomiting in patients undergoing thyroidectomy; Anaesthesiology - Anaesthetics

• Registration Number: ACTRN12612000757819
• Lead Sponsor: Astellas pharma korea, INC.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-07-16
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 69

Inclusion Criteria

patients undergoing thyroidectimy

Exclusion Criteria

severe impairment of bowel motility, insulin-dependent diabetes mellitus, pregnancy or breast feeding, administration of antiemetic medication within 24 h before operation, history of cardiovascular or respiratory disease, active alcohol or drug usage, obesity (body mass index > 35 kg/m2), impaired renal and/or hepatic function

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Severity of nausea assessed using 10 point-verbal numerical rating scale(VNRS)[at 0hr, 6hr, 12hr, 24hr postoperatively];Incidence of vomiting[at 0hr, 6hr, 12hr, 24hr postoperatively];Rescue antiemetic recorded by nurse[at 0hr, 6hr, 12hr, 24hr postoperatively]

Secondary Outcome Measures

Name	Time	Method
Pain score assessed using 10 point-verbal numerical rating scale(VNRS)[at 0hr, 6hr, 12hr, 24hr postoperatively];fentanyl consumption recorded by nurse[at 0hr, 6hr, 12hr, 24hr postoperatively]